Abstract
Purpose :
Studies have shown that long non-coding RNAs (lncRNAs) play an important role in the development and progression of ocular tumor. So far lncRNAs in the sebaceous gland carcinoma (SGC) are still poorly understood. Our preliminary results suggest that in the SGC the expression of lncRNA DUXAP8 and IL-6 significantly increased, but the expression of related microRNAs decreased, which suggest lncRNA DUXAP8 as a competitive endogenous RNA (ceRNA) regulates IL-6 signaling pathway, but the effect and mechanism of lncRNA DUXAP8 in the SGC remain to be further explored. Therefore, we hypothesized that lncRNA DUXAP8 can bind to specific microRNAs to competitively activate the expression of IL-6, which influence the expression of IL-6 and the downstream related genes, then lead to the development and progression of SGC.
Methods :
Total RNA was isolated from five biological replicates of human SGC tissues and normal sebaceous gland tissues, and then was processed for RNA sequencing (RNA-seq) and microRNA sequencing (microRNA-seq). We identified the differential expressed mRNAs, lncRNAs, microRNA and their correlation using bioinformatics methods. We detected the expression and binding of lncRNA DUXAP8, IL-6 and microRNA in the SGC and normal meibomian gland , with the methods of RNA immunoprecipitation (RIP), Real-time PCR, Western blot, adenovirus transfection, from the overall level of molecular and cellular.
Results :
We found the expression of lncRNA DUXAP8 and IL-6 significantly increased (p<0.05), but the expression of related microRNAs decreased (p<0.05) in the SGC using bioinformatics methods and Real-time PCR, then we also found lncRNA DUXAP8 can decreased the binding of Ago2 and related microRNAs in the SGC using the method of RIP (p<0.05).
Conclusions :
Our results are consistent with our hypothesis that lncRNA DUXAP8 as a ceRNA can bind to specific microRNAs to competitively activate the expression of IL-6, which influence the expression of IL-6 and the downstream related genes, then lead to the development and progression of SGC, which may provide new targets and ideas for the treatment of SGC.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.